| |
|
|
|
|
|
|
|||
|
Blood, 1 December 2006, Vol. 108, No. 12, pp. 3769-3776. Prepublished online as a Blood First Edition Paper on August 8, 2006; DOI 10.1182/blood-2006-03-008839.
IMMUNOBIOLOGY c-Rel plays a key role in deficient activation of B cells from a nonX-linked hyper-IgM patientFrom the Department of Cell Biology and Neuroscience, Rutgers, The State University of New Jersey, Piscataway; and Harbor General Hospital, University of CaliforniaLos Angeles, Torrance.
Our previous results demonstrated that B cells from a patient (pt1) with nonX-linked hyper-IgM syndrome (HIGM) possess an atypical CD23lo phenotype that is unaffected by CD40-mediated activation. To investigate the molecular mechanism underlying defective CD23 expression in pt1 B cells, we used lymphoblastoid cell lines that express LMP1 under the control of a tetracycline-inducible promoter (LCLtet). Our analysis revealed that the CD23lo phenotype in the pt1-LCLtet cells is a direct consequence of diminished CD23 transcription. We demonstrate a marked decrease in c-Relcontaining complexes that bind to the proximal CD23a/b promoters in pt1-LCLtet extracts, resulting from an overall lower expression of c-Rel in pt1-LCLtet cells. Analysis of c-Rel mRNA revealed relatively equal amounts in pt1-LCLtet and control LCLtet cells, indicating that diminished c-Rel protein expression is unrelated to decreased transcription. Finally, a critical role for c-Rel in CD23 regulation was demonstrated by effectively altering c-Rel expression that resulted in the direct modulation of CD23 surface expression. Collectively, these findings demonstrate that low levels of c-Rel are the underlying cause of aberrant CD23 expression in pt1 B cells and are likely to play a critical role in the pathophysiology of this form of HIGM.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2006 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||